Search

Your search keyword '"Hadders, Michael A."' showing total 147 results

Search Constraints

Start Over You searched for: Author "Hadders, Michael A." Remove constraint Author: "Hadders, Michael A."
147 results on '"Hadders, Michael A."'

Search Results

1. Delineation of a KDM2B-related neurodevelopmental disorder and its associated DNA methylation signature

4. Delineation of a KDM2B-related neurodevelopmental disorder and its associated DNA methylation signature

8. Mechanistic basis for Sgo1-mediated centromere localization and function of the CPC

9. Mechanistic basis for Sgo1-mediated centromere localization and function of the CPC

13. Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

16. Molecular Basis for CPC-Sgo1 Interaction: Implications for Centromere Localisation and Function of the CPC

17. Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B

18. Leave no sister behind

19. A highly conserved pocket on PP2A-B56 is required for hSgo1 binding and cohesion protection during mitosis

23. A Newborn Falsely Suspected of Congenital Hypothyroidism due to Mutated Thyroxine-Binding Globulin with Low Binding Affinity

24. A highly conserved binding pocket on PP2A-B56 is required for shugoshin binding and cohesion protection

26. Untangling the contribution of Haspin and Bub1 to Aurora B function during mitosis

28. A highly conserved pocket on PP2A-B56 is required for hSgo1 binding and cohesion protection during mitosis.

34. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells

38. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells

39. Structure-guided design of selective epac1 and epac2 agonists

41. Structure-guided design of selective epac1 and epac2 agonists

42. Detailed imaging and genetic analysis reveal a secondary BRAF(L) (505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

44. Sequential multisite phospho-regulation of KNL1-BUB3 interfaces at mitotic kinetochores

45. Structure-Guided Design of Selective Epac1 and Epac2 Agonists

46. Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

47. Detailed imaging and genetic analysis reveal a secondaryBRAFL505Hresistance mutation and extensive intrapatient heterogeneity in metastaticBRAFmutant melanoma patients treated with vemurafenib

Catalog

Books, media, physical & digital resources